Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: Results of a 3-month extension study

Journal of the Neurological Sciences

Volumn 299, Issue 1-2, 2010, Pages 179-183

  Muresanu, Dafin F ^a   Alvarez, X Anton ^b   Moessler, Herbert ^c   Novak, Philipp H ^c   Stan, Adina ^a   Buzoianu, Anca ^a   Bajenaru, Ovidiu ^d   Popescu, Bogdan O ^d,e  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Centro de Investigacion Biomedica EuroEspes   (Spain)

^c Ever Neuro Pharma ^*  (Austria)

^d CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

Author keywords

Cerebrolysin; Cognitive performance; QEEG slowing; Quantitative EEG; Vascular dementia

Indexed keywords

CEREBROLYSIN; PLACEBO;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROENCEPHALOGRAM; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIINFARCT DEMENTIA; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; QUANTITATIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; AMINO ACIDS; ANALYSIS OF VARIANCE; BRAIN; BRAIN MAPPING; COGNITION; DEMENTIA, VASCULAR; DOUBLE-BLIND METHOD; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78649513693     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2010.08.040     Document Type: Article

References (25)

1. G.C. Roman Vascular dementia may be the most common form of dementia in the elderly J Neurol Sci 203-204 2002 7 10
2. A.D. Korczyn The underdiagnosis of the vascular contribution to dementia J Neurol Sci 229-230 2005 3 6
3. B. Kuczynski, B. Reed, D. Mungas, M. Weiner, H.C. Chui, and W. Jagust Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease Arch Neurol 65 5 2008 650 655
4. M. Gawel, E. Zalewska, E. Szmidt-Sałkowska, and J. Kowalski The value of quantitative EEG in differential diagnosis of Alzheimer's disease and subcortical vascular dementia J Neurol Sci 283 1-2 2009 127 133
5. U. Schreiter Gasser, V. Rousson, F. Hentschel, H. Sattel, and T. Gasser Alzheimer disease versus mixed dementias: an EEG perspective Clin Neurophysiol 119 10 2008 2255 2259
6. M. Liedorp, W.M. van der Flier, E.L. Hoogervorst, P. Scheltens, and C.J. Stam Associations between patterns of EEG abnormalities and diagnosis in a large memory clinic cohort Dement Geriatr Cogn Disord 27 1 2009 18 23
7. W. Yin, A.P. Signore, M. Iwai, G. Cao, Y. Gao, and M.J. Johnnides Preconditioning suppresses inflammation in neonatal hypoxic ischemia via Akt activation Stroke 38 3 2007 1017 1024
8. L.C. Pettigrew, M.S. Kindy, S. Scheff, J.E. Springer, R.J. Kryscio, and Y. Li Focal cerebral ischemia in the TNFalpha-transgenic rat J Neuroinflammation 5 2008 47
9. P. Taishi, L. Churchill, M. Wang, D. Kay, C.J. Davis, and X. Guan TNFα siRNA reduces brain TNF and EEG delta wave activity in rats Brain Res 1156 2007 125 132
10. D.F. Muresanu, X.A. Alvarez, H. Moessler, M. Buia, A. Stan, and D. Pintea A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration J Neurol Sci 267 1-2 2008 112 119
11. X.A. Álvarez, R. Cacabelos, M. Laredo, V. Couceiro, C. Sampedro, and M. Varela A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's Disease Eur J Neurol 13 2006 46 54
12. G.L. Plosker, and S. Gauthier Cerebrolysin: a review of its use in dementia Drugs Aging 26 11 2009 893 915
13. E. Rockenstein, M. Torrance, M. Mante, A. Adame, A. Paulino, and J.B. Rose Cerebrolysin decreases amyloid-beta production by regulating amyloid precursor protein maturation in a transgenic model of Alzheimer's disease J Neurosci Res 83 2006 1252 1261
14. X.A. Álvarez, V. Lombardi, L. Fernández-Novoa, M. García, C. Sanpedro, and A. Cagiao Cerebrolysin reduces microglial activation in vivo and in vitro: a potential mechanism of neuroprotection J Neural Transm Suppl 59 2000 281 292
15. X.A. Alvarez, C. Sampedro, R. Cacabelos, C. Linares, M. Aleixandre, and M. García-Fantini Reduced TNF-alpha and increased IGF-I levels in the serum of Alzheimer patients treated with the neurotrophic agent Cerebrolysin Int J Neuropsychopharmacol 12 2009 867 872
16. R.C. Mohs, D. Knopman, R.C. Petersen, S.H. Ferris, C. Ernesto, and M. Grundman Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's disease assessment scale that broaden its scope Alzheimer Dis Assoc Disord An Int J 11 Suppl. 2 1997 S13 S21
17. G.C. Roman, T.K. Tatemichi, T. Erkinjuntti, J.L. Cummings, J.C. Masdeu, and J.H. Garcia Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop Neurology 43 2 1993 250 260
18. M. Folstein, S. Folstein, and P.R. McHugh Mini-mental state: a practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
19. K. Nagata, K. Tagawa, S. Hiroi, F. Shishido, and K. Uemura Electroencephalographic correlates of blood flow and oxygen metabolism provided by positron emission tomography in patients with cerebral infarction Electroencephalogr Clin Neurophysiol 72 1989 16 30 (Pubitemid 19014036)
20. X.A. Alvarez, C. Sanpedro, J. Figueroa, I. Tellado, A. González, and M. García-Fantini Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury J Neural Transm 115 2008 683 692
21. E. Masliah, F. Armasolo, I. Veinbergs, M. Mallory, and W. Samuel Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice Pharmacol Biochem Behav 62 1999 239 245
22. I. Reinprecht, A. Gschanes, M. Windisch, and G. Fachbach Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old rats Histochem J 31 1999 395 401
23. B. Szelies, R. Mielke, J. Kessler, and W.D. Heiss EEG power changes are related to regional cerebral glucose metabolism in vascular dementia Clin Neurophysiol 110 4 1999 615 620
24. R. Boado, W. Dafang, and M. Windisch In vivo upregulation of the blood-brain barrier GLUT-1 glucose transporter by brain-derived peptides Neurosci Res 34 1999 217 224
25. P.H. Novak, H. Moessler, E.I. Gusev, and A.B. Guekht Cerebrolysin in vascular dementia: a randomized, placebo controlled study Alzheimer's & Dementia 5 4 2009 P249